Natera (NASDAQ:NTRA) Stock Rating Lowered by StockNews.com

Natera (NASDAQ:NTRA) was downgraded by research analysts at StockNews.com from a “hold” rating to a “sell” rating in a note issued to investors on Friday.

NTRA has been the subject of a number of other research reports. Robert W. Baird raised their price objective on Natera from $117.00 to $120.00 and gave the stock an “outperform” rating in a research report on Friday, August 9th. Stephens restated an “overweight” rating and set a $125.00 price target on shares of Natera in a research note on Friday, August 9th. Piper Sandler reaffirmed an “overweight” rating and issued a $150.00 price objective on shares of Natera in a research report on Friday, September 13th. Morgan Stanley boosted their target price on shares of Natera from $125.00 to $132.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 13th. Finally, UBS Group decreased their price target on shares of Natera from $160.00 to $145.00 and set a “buy” rating for the company in a report on Friday, August 9th. One research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the stock. According to MarketBeat.com, Natera presently has an average rating of “Moderate Buy” and a consensus target price of $124.44.

Natera Price Performance

NTRA opened at $117.67 on Friday. The firm has a market capitalization of $14.55 billion, a PE ratio of -48.03 and a beta of 1.53. The company has a debt-to-equity ratio of 0.34, a current ratio of 4.14 and a quick ratio of 4.01. The business’s 50-day moving average is $123.24 and its two-hundred day moving average is $111.34. Natera has a 1 year low of $36.90 and a 1 year high of $133.54.

Natera (NASDAQ:NTRA) last issued its quarterly earnings data on Thursday, August 8th. The medical research company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.39. Natera had a negative net margin of 21.47% and a negative return on equity of 36.74%. The firm had revenue of $413.35 million for the quarter, compared to the consensus estimate of $343.00 million. During the same quarter in the previous year, the firm earned ($0.97) EPS. The company’s quarterly revenue was up 58.1% compared to the same quarter last year. Research analysts anticipate that Natera will post -1.96 earnings per share for the current fiscal year.

Insider Buying and Selling at Natera

In other news, CEO Steven Leonard Chapman sold 4,084 shares of the firm’s stock in a transaction that occurred on Monday, July 29th. The shares were sold at an average price of $102.77, for a total transaction of $419,712.68. Following the sale, the chief executive officer now owns 206,293 shares of the company’s stock, valued at $21,200,731.61. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other news, CEO Steven Leonard Chapman sold 4,084 shares of the stock in a transaction dated Monday, July 29th. The shares were sold at an average price of $102.77, for a total transaction of $419,712.68. Following the sale, the chief executive officer now directly owns 206,293 shares of the company’s stock, valued at $21,200,731.61. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Michael Burkes Brophy sold 691 shares of Natera stock in a transaction dated Friday, October 25th. The shares were sold at an average price of $118.81, for a total value of $82,097.71. Following the completion of the transaction, the chief financial officer now owns 72,709 shares of the company’s stock, valued at approximately $8,638,556.29. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 50,149 shares of company stock valued at $6,007,018. 7.60% of the stock is owned by company insiders.

Institutional Investors Weigh In On Natera

A number of institutional investors have recently added to or reduced their stakes in the stock. Itau Unibanco Holding S.A. purchased a new position in Natera during the second quarter valued at $28,000. Quarry LP raised its holdings in shares of Natera by 148.4% during the second quarter. Quarry LP now owns 318 shares of the medical research company’s stock valued at $34,000 after acquiring an additional 190 shares during the last quarter. GAMMA Investing LLC lifted its position in shares of Natera by 50.0% in the second quarter. GAMMA Investing LLC now owns 324 shares of the medical research company’s stock valued at $35,000 after acquiring an additional 108 shares in the last quarter. Tobam acquired a new stake in shares of Natera in the second quarter worth approximately $74,000. Finally, DekaBank Deutsche Girozentrale purchased a new stake in shares of Natera during the first quarter worth approximately $83,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.